Amgen has entered a collaboration with Novartis in the areas of Alzheimer’s disease and migraine using Novartis’ differentiated and genetically validated Alzheimer’s program directed at genetically predisposed individuals at risk. The collaboration also allows Amgen to focus on the commercialization of its migraine programs in the U.S., Canada and Japan, while leveraging Novartis’ commercial capabilities in neuroscience throughout Europe and other markets.   The agreement com...